Related Experiment Videos
Quinupristin/dalfopristin.
Joseph M Blondeau1, Stephen E Sanche
1Department of Clinical Microbiology, Saskatoon and District Health and the University of Saskatchewan, Canada. blondeauj@sdh.sk.ca
Expert Opinion on Pharmacotherapy
|August 21, 2002
Summary
Antimicrobial resistance in Gram-positive pathogens is increasing, limiting treatment options. Quinupristin/dalfopristin offers a viable therapeutic choice for infections caused by these resistant organisms.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Gram-positive pathogens cause significant community- and hospital-acquired infections.
- Increasing antimicrobial resistance, including penicillin-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA), complicates treatment.
- Emerging resistance among Gram-positive pathogens reduces effective therapeutic options.
Purpose of the Study:
- To review the frequency of Gram-positive pathogen recovery in infections.
- To discuss the escalating prevalence of antimicrobial resistance in Gram-positive pathogens.
- To evaluate quinupristin/dalfopristin as a treatment option for Gram-positive infections.
Main Methods:
- Literature review of infectious diseases and antimicrobial resistance data.
- Analysis of pathogen recovery rates and resistance trends.
- Evaluation of quinupristin/dalfopristin's spectrum of activity.
Main Results:
- Gram-positive pathogens are frequent causes of serious infections.
- Significant resistance to common antibiotics is observed in Gram-positive pathogens.
- Quinupristin/dalfopristin demonstrates activity against various resistant Gram-positive organisms.
Conclusions:
- Rising antimicrobial resistance necessitates alternative treatment strategies.
- Quinupristin/dalfopristin is an effective option for infections caused by resistant Gram-positive pathogens.
- This agent addresses the challenge of reduced therapeutic choices for Gram-positive infections.